BC Week In Review | Oct 14, 2013
Clinical News

Alphanate update

Grifols launched the SPIRIT registry to evaluate Alphanate in 100 patients with hemophilia A and inhibitors. Alphanate is approved in the U.S. to treat hemophilia A, congenital von Willebrand disease (vWD) and for use in...
BC Week In Review | Mar 21, 2011
Clinical News

Alphanate regulatory update

FDA approved an updated label for Grifols' Alphanate antihemophilic factor/ von Willebrand factor (vWF) complex to include that certain manufacturing steps have been shown to reduce the infectivity of an experimental transmissible spongiform encephalitis (TSE)...
BC Week In Review | Feb 12, 2007
Clinical News

Alphanate regulatory update

FDA approved an sBLA for Alphanate antihemophilic factor/ von Willebrand factor complex for patients undergoing surgery or invasive procedures with von Willebrand disease (vWD) in whom desmopressin is either ineffective or contraindicated. Alphanate is approved...
BC Week In Review | Feb 5, 2007
Clinical News

Alphanate regulatory update

FDA approved Alphanate, an antihemophilic factor/ von Willebrand factor complex, to treat congenital von Willebrand disease (VWD). Grifols S.A. , Barcelona, Spain   Product: Alphanate   Business: Hematology  ...
BioCentury | Nov 8, 1999
Tools & Techniques

Approved protein & antibody therapeutics

Approved protein & antibody therapeutics Company Product Indication Year first approved Alpha Therapeutic Albutein albumin Hypovolemic shock, hemodialysis and cardiopulmonary bypass 1986 Alphanate Factor VIII AlphaNine Factor IX Venoglobulin-S IgG Hemophilia A Hemophilia B Immunodeficiencies...
Items per page:
1 - 5 of 5